152 related articles for article (PubMed ID: 37983866)
1. Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy.
Lakkaniga NR; Wang Z; Xiao Y; Kharbanda A; Lan L; Li HY
Med Res Rev; 2024 Mar; 44(2):686-706. PubMed ID: 37983866
[TBL] [Abstract][Full Text] [Related]
2. Aurora-B kinase inhibitors for cancer chemotherapy.
Yeung SC; Gully C; Lee MH
Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
[TBL] [Abstract][Full Text] [Related]
3. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract][Full Text] [Related]
4. Aurora A and B kinases--targets of novel anticancer drugs.
Libertini S; Abagnale A; Passaro C; Botta G; Portella G
Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):219-41. PubMed ID: 20524930
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase inhibitors as anticancer molecules.
Katayama H; Sen S
Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
[TBL] [Abstract][Full Text] [Related]
6. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology.
de Almeida Magalhães T; de Sousa GR; Alencastro Veiga Cruzeiro G; Tone LG; Valera ET; Borges KS
J Mol Med (Berl); 2020 Apr; 98(4):495-512. PubMed ID: 32219470
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase inhibitors: progress towards the clinic.
Kollareddy M; Zheleva D; Dzubak P; Brahmkshatriya PS; Lepsik M; Hajduch M
Invest New Drugs; 2012 Dec; 30(6):2411-32. PubMed ID: 22350019
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
12. Update on aurora kinase inhibitors in gynecologic malignancies.
Tao X; Chon HS; Fu S; Kavanagh JJ; Hu W
Recent Pat Anticancer Drug Discov; 2008 Nov; 3(3):162-77. PubMed ID: 18991785
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase A inhibitors: promising agents in antitumoral therapy.
Malumbres M; Pérez de Castro I
Expert Opin Ther Targets; 2014 Dec; 18(12):1377-93. PubMed ID: 25200357
[TBL] [Abstract][Full Text] [Related]
14. Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.
Yan M; Wang C; He B; Yang M; Tong M; Long Z; Liu B; Peng F; Xu L; Zhang Y; Liang D; Lei H; Subrata S; Kelley KW; Lam EW; Jin B; Liu Q
Med Res Rev; 2016 Nov; 36(6):1036-1079. PubMed ID: 27406026
[TBL] [Abstract][Full Text] [Related]
15. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
17. Aurora-A kinase regulates NF-kappaB activity: lessons from combination studies.
Linardopoulos S
J BUON; 2007 Sep; 12 Suppl 1():S67-70. PubMed ID: 17935280
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
19. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.
Falchook GS; Bastida CC; Kurzrock R
Semin Oncol; 2015 Dec; 42(6):832-48. PubMed ID: 26615129
[TBL] [Abstract][Full Text] [Related]
20. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
